


American Shared Hospital Services (AMS)

NYSE; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0000744825

American Shared Hospital Services	
AMS; healthcare	
Grade	D  fourth fifth of 371 graded peers percentile 68.1; sampling error 2.5 points; lower is stronger
Rank	253 of 371
Profitability	D  percentile 72.5
Solvency	C  percentile 54.4
Growth and financing	B/C  percentile 37.7
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$55.5M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer not computable: distress
Inputs computable	10 of 14
Graded from	filings received through Mar 31, 2026 192 days before the rescans; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$1.48 2026-09-18; market equity \$9.8M
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C/D from Feb 21, 2025, C from Oct 21, 2025, C/D from Feb 21, 2026, D from Apr 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

American Shared Hospital Services ("ASHS" and, together with its subsidiaries, the "Company") is a leading provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The main drivers of the Company's revenue are numbers of sites, procedure volume, and reimbursement. The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 72.5						
Gross profitability		9.1%	32.2%	77.1	372	2025-12-31
Return on invested capital		(8.4%)	9.3%	80.8	74	2025-12-31
Accruals ratio		(8.0%)	(6.6%)	48.4	811	2025-12-31
Gross margin stability, five years		9.4 pts	2.8 pts	83.9	243	2025-12-31
Solvency, sleeve percentile 54.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		0.05	(0.31)	36.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Interest coverage		(2.28x)	(4.51x)	35.0	81	2025-12-31
Current ratio		0.76x	2.96x	91.6	839	2025-12-31
Growth and financing, sleeve percentile 37.7						
Revenue growth, three-year compound		12.5%	10.0%	44.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Asset growth, three years		8.1%	2.1%	34.4	704	2025-12-31
Net share issuance, one year		2.4%	2.5%	33.8	634	2026-03-25


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet
249	PTC Therapeutics, Inc. (PTCT)	67.0	D	
250	Cardiff Oncology, Inc. (CRDF)	67.3	D	short runway, fortress balance sheet
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.6	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	67.8	D	
253	American Shared Hospital Services (AMS) <	68.1	D	late filer
254	Orchestra BioMed Holdings, Inc. (OBIO)	68.4	D	dilution, short runway, fortress balance sheet
255	Adaptive Biotechnologies Corp. (ADPT)	68.6	D	
256	Iridex Corp. (IRIX)	68.9	D	fortress balance sheet
257	Lyell Immunopharma, Inc. (LYEL)	69.2	D	dilution, degenerate inputs
258	Iovance Biotherapeutics, Inc. (IOVA)	69.5	D	dilution, short runway

What the price implies

at the 2026-09-18 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(48.6%)	8.0%	15
Distance from 52-week high	(45.5%)	(31.4%)	32
EBIT to enterprise value	(19.3%)	(1.5%)	24
Free cash flow yield	(51.3%)	(1.0%)	11
Book value to price	2.61	0.28	98
Sales to price	3.18	0.31	94
Composite equity issuance, five years	13.7%	20.3%	44
Relative strength against the sector, log excess return	(0.88)	(0.14)	15

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail

Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$6.5M
Operating cash flow, four quarters	\$5.4M
Months of runway	not finite
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$14,745

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$5.1M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
2	assets	us-gaap:Assets	\$55.5M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
3	operating income	us-gaap:OperatingIncomeLoss	-\$3.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$3.2M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$493,000	2025-12-31	2026-03-31	10-K	0001437749-26-010731
6	total debt	us-gaap:LongTermDebt	\$17.4M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
7	book equity	us-gaap:StockholdersEquity	\$24.0M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.5M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
9	total debt	us-gaap:LongTermDebt	\$20.4M	2024-12-31	2025-04-04	10-K	0001437749-25-011052
10	book equity	us-gaap:StockholdersEquity	\$25.2M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$11.0M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
12	net income	us-gaap:NetIncomeLoss	-\$1.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.1M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
14	assets	us-gaap:Assets	\$60.2M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$28.1M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
16	gross profit	us-gaap:GrossProfit	\$9.2M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$28.3M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
18	gross profit	us-gaap:GrossProfit	\$9.3M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$21.3M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
20	gross profit	us-gaap:GrossProfit	\$8.4M	2022-12-31	2024-04-01	10-K	0001437749-24-010308
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$19.7M	2022-12-31	2024-04-01	10-K	0001437749-24-010308
22	gross profit	us-gaap:GrossProfit	\$6.7M	2021-12-31	2023-03-31	10-K	0001437749-23-008796
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$17.6M	2021-12-31	2023-03-31	10-K	0001437749-23-008796
24	current assets	us-gaap:AssetsCurrent	\$17.7M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
25	current liabilities	us-gaap:LiabilitiesCurrent	\$23.4M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$4.3M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
27	liabilities	us-gaap:Liabilities	\$27.8M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
28	total debt	us-gaap:LongTermDebt	\$13.3M	2023-12-31	2024-04-01	10-K	0001437749-24-010308
29	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$13.7M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
30	operating income	us-gaap:OperatingIncomeLoss	\$270,000	2023-12-31	2025-04-04	10-K	0001437749-25-011052
31	depreciation amortization	us-gaap:Depreciation	\$5.2M	2023-12-31	2024-04-01	10-K	0001437749-24-010308
32	interest expense	us-gaap:InterestExpense	\$1.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010731
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$167,000	2024-12-31	2026-03-31	10-K	0001437749-26-010731
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.9M	2024-12-31	2026-03-31	10-K	0001437749-26-010731
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.7M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.3M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.2M	2022-12-31	2024-04-01	10-K	0001437749-24-010308
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$388,000	2022-12-31	2024-04-01	10-K	0001437749-24-010308
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$636,000	2023-12-31	2025-04-04	10-K	0001437749-25-011052
41	income tax	us-gaap:IncomeTaxExpenseBenefit	\$431,000	2023-12-31	2025-04-04	10-K	0001437749-25-011052
42	current assets	us-gaap:AssetsCurrent	\$20.5M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
43	current liabilities	us-gaap:LiabilitiesCurrent	\$10.8M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
44	current assets	us-gaap:AssetsCurrent	\$18.7M	2022-12-31	2024-04-01	10-K	0001437749-24-010308
45	current liabilities	us-gaap:LiabilitiesCurrent	\$5.2M	2022-12-31	2024-04-01	10-K	0001437749-24-010308

46	assets	us-gaap:Assets	\$48.2M	2023-12-31	2025-04-04	10-K	0001437749-25-011052
47	assets	us-gaap:Assets	\$44.0M	2022-12-31	2024-04-01	10-K	0001437749-24-010308
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,602,000	2026-03-25	2026-03-31	10-K	0001437749-26-010731
49	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,450,000	2025-03-25	2025-04-04	10-K	0001437749-25-011052